Loading company…
Rivus Pharmaceuticals develops treatments for cardio-metabolic health, including its candidate HU6.
Founded in 2019 and based in Virginia, US, Rivus Pharmaceuticals develops therapies for cardio-metabolic disease. Its small molecule candidate HU6 is a controlled metabolic accelerator being studied for obesity and related disorders. In September 2022, the company raised USD 132 million in Series B funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in